Elsevier

Journal of Hepatology

Volume 56, Issue 2, February 2012, Pages 448-454
Journal of Hepatology

Research Article
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies

https://doi.org/10.1016/j.jhep.2011.05.029Get rights and content

Background & Aims

Non-alcoholic fatty liver disease (NAFLD) is a complex disease trait where genetic variations and environment interact to determine disease progression. The association of PNPLA3 with advanced disease has been consistently demonstrated but many other modifier genes remain unidentified. In NAFLD, increased fatty acid oxidation produces high levels of reactive oxygen species. Manganese-dependent superoxide dismutase (MnSOD), encoded by the SOD2 gene, plays an important role in protecting cells from oxidative stress. A common non-synonymous polymorphism in SOD2 (C47T; rs4880) is associated with decreased MnSOD mitochondrial targeting and activity making it a good candidate modifier of NAFLD severity.

Methods

The relevance of the SOD2 C47T polymorphism to fibrotic NAFLD was assessed by two complementary approaches: we sought preferential transmission of alleles from parents to affected children in 71 family trios and adopted a case-control approach to compare genotype frequencies in a cohort of 502 European NAFLD patients.

Results

In the family study, 55 families were informative. The T allele was transmitted on 47/76 (62%) possible occasions whereas the C allele was transmitted on only 29/76 (38%) occasions, p = 0.038. In the case control study, the presence of advanced fibrosis (stage >1) increased with the number of T alleles, p = 0.008 for trend. Multivariate analysis showed susceptibility to advanced fibrotic disease was determined by SOD2 genotype (OR 1.56 (95% CI 1.09–2.25), p = 0.014), PNPLA3 genotype (p = 0.041), type 2 diabetes mellitus (p = 0.009) and histological severity of NASH (p = 2.0 × 10−16).

Conclusions

Carriage of the SOD2 C47T polymorphism is associated with more advanced fibrosis in NASH.

Introduction

Non-alcoholic fatty liver disease (NAFLD), widely considered to be the hepatic manifestation of the metabolic syndrome, encompasses a spectrum of liver disease from simple steatosis (fatty liver) through non-alcoholic steatohepatitis (NASH) to fibrosis and ultimately cirrhosis in the absence of alcohol abuse [1]. The prevalence of NAFLD is rapidly increasing and it is now the most common cause of chronic liver disease in Western countries [2]. Despite its high prevalence, only a minority of patients with steatosis progress to develop inflammation and less than a quarter of subjects with NAFLD ever progress beyond steatosis to significant fibrosis and cirrhosis [3], [4].

NAFLD is best considered a complex disease trait where subtle inter-patient variations including host genetic factors and environment interact to produce disease phenotype and determine disease progression [5], [6], [7]. Basic science is helping to elucidate the mechanisms perpetuating liver cell injury and fibrosis in NAFLD through in vitro and in vivo studies. Attention is currently focused on the role of increased free fatty acid (FFA) flux on a background of insulin resistance as key drivers of pathogenesis through hepatocellular oxidative stress secondary to reactive oxygen species (ROS) production during β- and ω-FFA oxidation, direct lipotoxicity, cytokine release and endoplasmic reticulum stress. Consequent cellular damage triggers a mixture of immune mediated hepatocellular injury and both necrotic and apoptotic cell death pathways [8], [9], [10], [11]. Persistence of these processes culminates in hepatic fibrosis [12].

Whilst the reasons for the apparent variation in individual susceptibility to progressive disease are incompletely understood, family/ethnic studies suggest that genetic factors play a significant role [13], [14]. Accordingly, genes encoding proteins influencing the magnitude of these different forms of cellular stress are obvious candidates as genetic factors contributing to susceptibility to progressive NAFLD [5]. Single nucleotide polymorphisms (SNPs) in several candidate genes involved in inflammation, oxidative stress and fibrogenesis have been associated with the severity of liver damage in NAFLD (reviewed [5]). As yet, only the association of PNPLA3 with advanced NASH has been consistently replicated in large studies [5].

The mitochondrial enzyme manganese-dependent superoxide dismutase (MnSOD), encoded by the nuclear SOD2 gene, plays an important role in protecting cells from superoxide radicals [15]. SOD2 is subject to a common polymorphism (C47T, rs4880) which results in an amino acid substitution in the signal sequence targeting the enzyme to the mitochondrion (Ala16Val) and may induce a conformational change in the protein tertiary structure [16]. The presence of alanine at position −9 in this sequence (C47 allele) has been demonstrated to be associated with more efficient protein import than valine (T47 allele) by in vitro expression studies and is predicted to result in higher enzyme activity [17], [18]. This SOD2 polymorphism (rs4880) has been investigated as a possible susceptibility factor in NASH and several other diseases where oxidative stress is considered to play a role in pathogenesis including hereditary hemochromatosis [19] and drug induced liver injury [20]. A small study in 63 Japanese patients found a significantly increased prevalence of the lower activity homozygous T genotype among cases [21]. More recently, the homozygous T genotype was reported to be associated with an increased incidence of diabetic nephropathy in large studies of type 1 diabetics from Sweden [22] and Denmark [23] and with susceptibility to pancreatic cancer in a US-based study [24]. SOD2 has also been investigated in relation to susceptibility to alcoholic liver disease but the results have been inconsistent and inconclusive [25], [26].

To further examine this biologically plausible association between SOD2 genotype and susceptibility to fibrosing steatohepatitis, we have used two complementary approaches. Firstly, we have carried out a family study analyzing trios consisting of children with fibrotic NAFLD and their two parents in which we have performed transmission disequilibrium test (TDT) analysis to determine whether there is preferential transmission of a particular parental allele to the affected children [27]. Secondly, we performed a classical case-control allelic association study in unrelated patients with NAFLD of varying severity including five times more patients than that reported previously [21].

Section snippets

Patients

A large patient cohort was recruited across centers in UK and Italy. The study had all necessary ethical approvals in both countries and all participants (or their parents) gave informed consent.

The Italian family study, collected DNA from 71 Italian family ‘trios’ in Rome (210 individuals) each comprising two living parents and an index child with biopsy-proven fibrotic NAFLD. Other causes of liver disease were excluded, including increased alcohol intake, chronic viral hepatitis, autoimmune

The SOD2 C47T allele is preferentially transmitted to children with fibrosing steatohepatitis

In the Italian family study, 61 out of the 71 children had fibrosing steatohepatitis (59 patients exhibited stage 1 fibrosis and 2 patients had stage 2 disease). Transmission disequilibrium testing (TDT) [27] was used to seek preferential transmission of either SOD2 allele to affected children in the family study. For SOD2 rs4880, 55 out of the 71 families were informative in that one or both parents were heterozygous for this SNP. In these families, the T allele was transmitted on 47/76 (62%)

Discussion

Using both case-control and intra-familial association methodologies, we have shown a consistent association between a functional SNP in the mitochondrial targeting sequence of SOD2 and fibrosis severity in NAFLD. These results provide persuasive genetic evidence that mitochondria-derived oxidative stress is important in the pathogenesis of advanced NAFLD. In particular, use of TDT analysis in a young NAFLD population is a novel feature. In addition, we have also demonstrated a strong

Conflict of interest

The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Acknowledgements

Q.M.A. is the recipient of a Clinical Senior Lectureship Award from the Higher Education Funding Council for England (HEFCE). Q.M.A., A.K.D. and C.P.D. are recipients of an MRC Programme Grant to identify and study novel genetic modifiers of liver disease and are members of the FLIP research consortium funded by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement Health-F2-2009-241762.

References (60)

  • S.F. Stewart et al.

    Valine–alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis

    Hepatology

    (2002)
  • L. Valenti et al.

    Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease

    Gastroenterology

    (2002)
  • E.M. Brunt et al.

    Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

    Am J Gastroenterol

    (1999)
  • J. Lenart et al.

    Deficiency of manganese superoxide dismutase in hepatocytes disrupts zonated gene expression in mouse liver

    Arch Biochem Biophys

    (2007)
  • D. Pessayre et al.

    NASH: a mitochondrial disease

    J Hepatol

    (2005)
  • R. Bataller et al.

    Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal

    Hepatology

    (2003)
  • Q.M. Anstee et al.

    Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies

    J Thromb Haemost

    (2008)
  • S. Merat et al.

    Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

    J Hepatol

    (2003)
  • M.F. Abdelmalek et al.

    Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

    Am J Gastroenterol

    (2001)
  • J.E. Lavine

    Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study

    J Pediatr

    (2000)
  • F.S. Facchini et al.

    Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease

    Gastroenterology

    (2002)
  • S.A. Harrison et al.

    Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

    Am J Gastroenterol

    (2003)
  • J.F. Dufour et al.

    Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

    Clin Gastroenterol Hepatol

    (2006)
  • L. Cortez-Pinto et al.

    Non-alcoholic steatohepatitis: from cell biology to clinical practice

    J Hepatol

    (2006)
  • I.R. Wanless et al.

    Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

    Hepatology

    (1990)
  • Q.M. Anstee et al.

    Genetics of alcoholic and non-alcoholic fatty liver disease

    Semin Liver Dis

    (2011)
  • Q.M. Anstee et al.

    Mouse models in non-alcoholic fatty liver disease and steatohepatitis research

    Int J Exp Pathol

    (2006)
  • H. Malhi et al.

    Apoptosis and necrosis in the liver: a tale of two deaths?

    Hepatology

    (2006)
  • G.C. Farrell et al.

    Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression

    J Gastroenterol Hepatol

    (2009)
  • J.P. Iredale

    Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ

    J Clin Invest

    (2007)
  • Cited by (151)

    • Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis

      2024, Journal of Interferon and Cytokine Research
    View all citing articles on Scopus
    View full text